Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field

Tokyo and Deventer, Netherlands (ots/PRNewswire) - Terumo Corporation (TSE:
4543) today announced it has completed the acquisition of Quirem Medical B.V., a
Netherlands-based healthcare startup specializing in the development of
next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a
treatment for liver tumors. Under the terms of the agreement, Terumo acquired
80.1% of the shares of Quirem Medical. This is over and above its current share
position of 19.9%, making Quirem Medical now a wholly owned subsidiary of
Terumo.

Terumo will make a one-time, up-front payment of USD 20 million with up to USD
25 million additional payments based on the achievement of future milestones by
2030. It will be funded through cash on hand and will not significantly impact
the company's financial projections for the current fiscal year ending March 31,
2021.

Quirem Medical has developed and manufactures QuiremSpheres(TM), the only
commercially available microspheres containing the radioactive isotope
Holmium-166. Recent trials have shown the safety and efficacy of holmium
microspheres for the treatment of unresectable liver cancer. To improve patient
selection, therapy planning and treatment verification, QuiremSpheres can be
visualized and quantified even in low concentrations by means of Single-Photon
Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). This
is unique and cannot be done with currently available Yttrium-90 based
microspheres.

Furthermore, Quirem Medical also produces QuiremScout(TM), a low dose holmium
microsphere that helps evaluate the biodistribution of microspheres prior to
therapy, and a dosimetry software package, Q-Suite(TM), which is used to plan
QuiremSpheres treatments based on QuiremScout dose imaging. Q-Suite is also able
to determine SIRT success immediately after the procedure by converting SPECT
and MR imaging into absorbed dose distributions. Together, these three
integrated products (QuiremSpheres, QuiremScout and Q-Suite) make up the full
Holmium SIRT Platform. The Holmium Platform equips physicians with the necessary
tools to optimize SIRT outcomes through more personalized treatment, addressing
the individual needs of each patient.

QuiremSpheres, QuiremScout and Q-Suite are CE-Marked and currently available in
Europe, the Middle East and Africa (EMEA). In the coming years, Terumo intends
to launch the Holmium Platform globally as part of the ongoing expansion of its
interventional oncology (IO) portfolio.